TY - JOUR
T1 - Regulatory T cells
T2 - Pathophysiological roles and clinical applications
AU - Sakai, Ryota
AU - Komai, Kyoko
AU - Iizuka-Koga, Mana
AU - Yoshimura, Akihiko
AU - Ito, Minako
N1 - Funding Information:
This work was supported by JSPS KAKENHI (S) JP17H06175, Challenging Research (P) JP18H05376, and AMED-CREST JP18gm0510019 and JP19gm1110009 grants to AY; JSPS KAKENHI 17K15667, 19H04817, and 19K16618 to MI; the Takeda Science Foundation; the Uehara Memorial Foundation; the Kanae Foundation; and the SENSHIN Medical Research Foundation, Keio Gijuku Academic Development Funds.
Publisher Copyright:
© 2019 by The Keio Journal of Medicine.
PY - 2020
Y1 - 2020
N2 - Inflammation and immune responses after tissue injury play pivotal roles in the resolution of inflam-mation, tissue recovery, fibrosis, and remodeling. Regulatory T cells (Tregs) are responsible for immune tolerance and are usually activated in secondary lymphatic tissues. Activated Tregs subsequently regulate effector T cell and dendritic cell activation. For clinical applications such as the suppression of both autoimmune diseases and the rejection of transplanted organs, methods to generate stabilized an-tigen-specific Tregs are required. For this purpose, transcriptional and epigenetic regulation of Foxp3 expression has been investigated. In addition to conventional Tregs, there are some Tregs that reside in tissues and are called tissue Tregs. Tissue Tregs exhibit tissue-specific functions that contribute to the maintenance of tissue homeostasis and repair. Such tissue Tregs could also be useful for Treg-based cell therapy. We recently discovered brain Tregs that accumulate in the brain during the chronic phase of ischemic brain injury. Brain Tregs resemble other tissue Tregs, but are unique in expressing neural cell-specific genes such as the serotonin receptor (Htr7); consequently, brain Tregs respond to sero-tonin. Here, we describe our experiences in the use of Tregs to suppress graft-versus-host disease and to promote neural recovery after stroke.
AB - Inflammation and immune responses after tissue injury play pivotal roles in the resolution of inflam-mation, tissue recovery, fibrosis, and remodeling. Regulatory T cells (Tregs) are responsible for immune tolerance and are usually activated in secondary lymphatic tissues. Activated Tregs subsequently regulate effector T cell and dendritic cell activation. For clinical applications such as the suppression of both autoimmune diseases and the rejection of transplanted organs, methods to generate stabilized an-tigen-specific Tregs are required. For this purpose, transcriptional and epigenetic regulation of Foxp3 expression has been investigated. In addition to conventional Tregs, there are some Tregs that reside in tissues and are called tissue Tregs. Tissue Tregs exhibit tissue-specific functions that contribute to the maintenance of tissue homeostasis and repair. Such tissue Tregs could also be useful for Treg-based cell therapy. We recently discovered brain Tregs that accumulate in the brain during the chronic phase of ischemic brain injury. Brain Tregs resemble other tissue Tregs, but are unique in expressing neural cell-specific genes such as the serotonin receptor (Htr7); consequently, brain Tregs respond to sero-tonin. Here, we describe our experiences in the use of Tregs to suppress graft-versus-host disease and to promote neural recovery after stroke.
UR - http://www.scopus.com/inward/record.url?scp=85082542473&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85082542473&partnerID=8YFLogxK
U2 - 10.2302/kjm.2019-0003-OA
DO - 10.2302/kjm.2019-0003-OA
M3 - Review article
C2 - 31353330
AN - SCOPUS:85082542473
SN - 0022-9717
VL - 69
SP - 1
EP - 15
JO - Keio Journal of Medicine
JF - Keio Journal of Medicine
IS - 1
ER -